Last reviewed · How we verify
TRAVERT 10% IN PLASTIC CONTAINER (INVERT SUGAR)
TRAVERT 10% IN PLASTIC CONTAINER (generic name: INVERT SUGAR) is a drug developed by BAXTER HLTHCARE. It is currently FDA-approved.
At a glance
| Generic name | INVERT SUGAR |
|---|---|
| Sponsor | BAXTER HLTHCARE |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Postprandial Glycemic Response to Berry Nectars Containing Inverted Sugar (NA)
- Evaluation of Intestinal Microbiota Manipulation to Treat Resistant Hypertension (NA)
- A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors (Phase 1)
- Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Lo (Phase 2)
- Research on the Lymphoma Staging and Therapeutic Evaluation of 18F-FDG PET/CT Comparing With Whole Body MRI IVIM Functional Imaging (NA)
- New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy: Feasibility of Insulin Dosing Based on Information From Continuous Glucose Monitoring (Phase 3)
- A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer (Phase 2)
- Optimisation of Acute Medium Chain Triglycerides Intake Characteristics on Different Plasma Metabolites in Young and Older Participants (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRAVERT 10% IN PLASTIC CONTAINER CI brief — competitive landscape report
- TRAVERT 10% IN PLASTIC CONTAINER updates RSS · CI watch RSS
- BAXTER HLTHCARE portfolio CI
Frequently asked questions about TRAVERT 10% IN PLASTIC CONTAINER
What is TRAVERT 10% IN PLASTIC CONTAINER?
TRAVERT 10% IN PLASTIC CONTAINER (INVERT SUGAR) is a pharmaceutical drug developed by BAXTER HLTHCARE.
Who makes TRAVERT 10% IN PLASTIC CONTAINER?
TRAVERT 10% IN PLASTIC CONTAINER is developed and marketed by BAXTER HLTHCARE (see full BAXTER HLTHCARE pipeline at /company/baxter).
What is the generic name of TRAVERT 10% IN PLASTIC CONTAINER?
INVERT SUGAR is the generic (nonproprietary) name of TRAVERT 10% IN PLASTIC CONTAINER.
What development phase is TRAVERT 10% IN PLASTIC CONTAINER in?
TRAVERT 10% IN PLASTIC CONTAINER is FDA-approved (marketed).
Related
- Manufacturer: BAXTER HLTHCARE — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing